Pediatric Waivers Contingent On Study Attempts In Sub-Populations - FDA
Executive Summary
Sponsors may have to attempt pediatric studies in small patient populations before FDA grants a pediatric waiver, FDA suggests in a list of "Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric 'Rule,' and Their Interaction" posted on its website July 27.
You may also be interested in...
"Me-Too" Drug Pediatric Study Should Await Safety Data From Marketing
"Me-too" drugs could be required to include statements recommending use of competitor drugs as part of the "pediatric use" section of labeling, FDA's final pediatric rule indicates.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials